Ultragenyx Pharmaceutical Inc.

https://www.ultragenyx.com/

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company dedicated to the research, development, and commercialization of novel products for serious rare and ultra-rare genetic diseases. Its mission is to bring life-altering treatments to patients with conditions that often have limited or no approved therapeutic options. The company's headquarters are located in Novato, California, USA.

The company's portfolio includes several approved therapies such as Crysvita (burosumab) for X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for mucopolysaccharidosis VII (MPS VII), and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders (LC-FAOD). Ultragenyx also markets Evkeeza (evinacumab) outside the U.S. for homozygous familial hypercholesterolemia (HoFH). The company focuses on genetically defined rare diseases, utilizing diverse drug modalities including biologics, small molecules, gene therapies (AAV), and antisense oligonucleotides (ASO).

Led by Founder, President, and CEO Emil Kakkis, Ultragenyx is a commercial-stage biopharmaceutical company with a robust clinical pipeline. In April 2026, the U.S. FDA accepted the Biologics License Application (BLA) resubmission for UX111 AAV gene therapy for Sanfilippo syndrome type A (MPS IIIA), with a PDUFA action date set for September 19, 2026. Additionally, the company reported positive 36-week data from a Phase 3 study of DTX301 AAV8 gene therapy for Ornithine Transcarbamylase (OTC) Deficiency in March 2026. Ultragenyx has also outlined a restructuring plan in early 2026 to reduce operating expenses and target profitability in 2027, and operates its own gene therapy manufacturing facility in Bedford, Massachusetts.

Latest updates

Ultragenyx Schedules Q1 2026 Earnings Call Amid Rare Disease Market Scrutiny

Event summary

  • Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) will host a conference call on May 5, 2026, at 5:00 p.m. ET.
  • The call will cover financial results and a corporate update for the quarter ending March 31, 2026.
  • A live webcast and replay (available for three months) will be accessible via the company's investor relations website.
  • Ultragenyx focuses on developing therapies for serious and ultra-rare genetic diseases.

The big picture

Ultragenyx operates in a highly specialized and competitive segment of the biopharmaceutical industry, where the development of therapies for rare diseases often carries significant regulatory and commercial hurdles. The company's strategy of prioritizing speed and cost-efficiency is a direct response to the challenges of bringing niche drugs to market, but success hinges on demonstrating tangible progress and achieving commercial traction. The upcoming earnings call will provide a key data point for assessing whether Ultragenyx can deliver on its promises in this demanding landscape.

What we're watching

Market Pressure
Increased investor scrutiny of rare disease valuations may influence Ultragenyx's stock performance following the earnings release, particularly given the high price tags associated with these therapies.
Pipeline Progress
The company's stated focus on 'time- and cost-efficient drug development' will be tested as investors assess the progress of its product candidates and the likelihood of regulatory approvals.
Commercialization
The ability of Ultragenyx to effectively commercialize its approved therapies will be critical to sustaining growth and justifying its current valuation.

Ultragenyx Gene Therapy for Sanfilippo Syndrome Nears FDA Decision

Event summary

  • Ultragenyx received FDA acceptance for a resubmitted Biologics License Application (BLA) for UX111, a gene therapy for Sanfilippo syndrome Type A.
  • The FDA has set a PDUFA action date of September 19, 2026, for the review.
  • UX111 would be the first approved therapy for Sanfilippo syndrome Type A, a rare, fatal neurodegenerative disorder.
  • Long-term clinical data, spanning up to 8 years, were included in the resubmission and presented at WORLDSymposium™ 2026.

The big picture

The acceptance of UX111’s BLA represents a significant milestone in the development of gene therapies for rare neurological disorders, a market increasingly attracting investment. While the therapy addresses a small patient population (estimated 3,000-5,000 globally), the lack of existing treatments commands a premium price, potentially generating substantial revenue if approved. The FDA’s decision will serve as a key indicator for the broader AAV gene therapy field, particularly for companies targeting other rare genetic diseases.

What we're watching

Regulatory Risk
The FDA’s review hinges on the acceptance of long-term data; a rejection or request for additional studies could significantly delay approval and impact Ultragenyx’s valuation.
Manufacturing Scale
Successful commercialization depends on Ultragenyx’s ability to scale manufacturing at both Andelyn Biosciences and its own facility; production bottlenecks could limit supply and revenue potential.
Market Adoption
Given the disease's rarity and the therapy's high price point, market adoption will be heavily influenced by reimbursement policies and patient access programs, which could impact revenue projections.

Ultragenyx Secures FDA Nod for GNE Myopathy Prodrug, UX016

Event summary

  • Ultragenyx received FDA clearance for an Investigational New Drug (IND) application for UX016, a sialic acid prodrug targeting GNE myopathy.
  • A Phase 1/2 clinical trial is planned to begin in the second half of 2026, enrolling approximately 24 adult patients in the U.S.
  • The clinical trial will evaluate safety, efficacy, pharmacokinetics, and muscle strength measures over 48 weeks.
  • UX016’s development is externally funded by a patient group, representing an innovative funding model.

The big picture

Ultragenyx's advancement of UX016 highlights the growing focus on ultra-rare genetic diseases, where patient advocacy groups are increasingly playing a role in funding drug development. The innovative funding model, while potentially beneficial, also introduces a unique set of risks compared to traditional venture capital or institutional investment. This approach underscores the challenges and opportunities in developing therapies for conditions affecting small patient populations.

What we're watching

Clinical Efficacy
The Phase 1/2 trial results will be critical in determining UX016's ability to meaningfully impact muscle function and disease progression in GNE myopathy patients, a key risk given the disease's severity.
Funding Sustainability
The reliance on philanthropic funding introduces a potential vulnerability; the long-term sustainability of this funding model will be a factor in UX016's continued development.
Regulatory Pathway
Given the rarity of GNE myopathy, the FDA's willingness to accept novel endpoints and potentially accelerated approval pathways will influence the overall timeline and commercial prospects for UX016.

Ultragenyx Gene Therapy Shows Promise in OTC Deficiency Trial

Event summary

  • Ultragenyx's DTX301 gene therapy demonstrated an 18% reduction in 24-hour plasma ammonia (AUC0-24) compared to placebo in a Phase 3 trial (Enh3ance study) at 36 weeks (p=0.018).
  • Eight of nine patients with abnormal ammonia levels at baseline achieved normal levels following DTX301 treatment, with levels generally maintained.
  • Patients receiving DTX301 reduced ammonia scavenger medication use by 27% and increased protein intake by approximately 13% while maintaining ammonia control.
  • The study enrolled 37 patients across 10 countries and 16 sites, with crossover planned for 64-week data in H1 2027.
  • The company expects to release data on treatment burden reduction (scavenger use and diet) in the first half of 2027.

The big picture

Ultragenyx's Phase 3 data represents a significant step forward for gene therapy in rare diseases, particularly for conditions like OTC deficiency where current treatments are burdensome and carry significant risk. The ability to reduce medication and dietary restrictions while maintaining ammonia control is a compelling value proposition, but the high cost of gene therapies and potential for immune reactions remain significant hurdles for broader adoption. The success of DTX301 could validate Ultragenyx's gene therapy platform and attract further investment in the rare disease space.

What we're watching

Regulatory Pathway
The FDA and EMA will likely scrutinize the 64-week data, particularly regarding long-term safety and efficacy, to determine the approval pathway for DTX301.
Market Adoption
The success of DTX301 will depend on physician and patient acceptance of gene therapy, given the high cost and potential for immune responses.
Competitive Landscape
Other companies are developing therapies for OTC deficiency; Ultragenyx's ability to secure market share will hinge on demonstrating a clear advantage over existing and emerging treatments.

Ultragenyx Secures Priority Review for Novel GSDIa Gene Therapy

Event summary

  • Ultragenyx received FDA acceptance for its Biologics License Application (BLA) for DTX401, a gene therapy for Glycogen Storage Disease Type Ia (GSDIa).
  • The FDA granted DTX401 Priority Review, setting a PDUFA action date of August 23, 2026.
  • Data from the Phase 3 GlucoGene study demonstrated clinically meaningful reductions in cornstarch intake and hypoglycemia, alongside improved quality of life.
  • DTX401 will be manufactured in the U.S. at Ultragenyx’s Bedford, Massachusetts facility.

The big picture

DTX401 represents a significant advancement in the treatment of GSDIa, a rare disease with limited therapeutic options. The Priority Review designation underscores the FDA’s recognition of the unmet medical need and the potential clinical benefit of gene therapy. However, the success of DTX401 will depend on navigating manufacturing complexities, securing favorable reimbursement, and demonstrating long-term efficacy and safety in a small patient population.

What we're watching

Regulatory Risk
The FDA’s review process remains unpredictable, and a potential rejection or request for additional data could significantly delay approval and impact Ultragenyx’s valuation.
Manufacturing Scale
Successful commercialization hinges on Ultragenyx’s ability to scale production at its Bedford facility to meet potential demand, given the therapy’s complexity and the relatively small patient population.
Market Adoption
The high cost of gene therapies will likely limit patient access, and Ultragenyx will need to demonstrate a compelling value proposition to payers and navigate potential reimbursement challenges.

Ultragenyx Restructures Amidst Revenue Growth, Eyes 2027 Profitability

Event summary

  • Ultragenyx reported $673 million in total revenue for 2025, a 20% increase year-over-year, driven primarily by Crysvita revenue of $481 million.
  • The company initiated a strategic restructuring plan, resulting in a 10% workforce reduction (approximately 130 employees).
  • Ultragenyx projects revenue between $730 million and $760 million for 2026, excluding potential revenue from new product launches.
  • The company anticipates achieving profitability in 2027, supported by expense reductions and revenue growth.

The big picture

Ultragenyx's restructuring reflects a broader trend in the biopharmaceutical sector, where companies are facing pressure to demonstrate a clear path to profitability amidst high R&D costs and regulatory hurdles. The company's reliance on a few key products, particularly Crysvita, makes it vulnerable to competition and pricing pressures. The success of its gene therapy pipeline, especially UX111 and GTX-102, will be critical for long-term growth and shareholder value.

What we're watching

Regulatory Risk
The Incomplete Response Letter (IRL) regarding UX111 signals potential delays and increased scrutiny from the FDA, which could impact timelines and revenue projections. Whether Ultragenyx can address the FDA's concerns and resubmit a successful BLA remains a key uncertainty. The company's ability to provide the requested documentation will be critical to future approval timelines and investor confidence.
Execution Risk
The success of the restructuring plan hinges on Ultragenyx’s ability to execute expense reductions while maintaining critical R&D momentum. How effectively the company manages the balance between cost-cutting and innovation will determine its path to profitability in 2027.
Clinical Catalysts
The pivotal Phase 3 data readout for GTX-102 in Angelman syndrome represents a significant potential revenue driver. The pace at which this data is released and its subsequent impact on market perception will be crucial for Ultragenyx’s valuation.

Ultragenyx to Detail 2025 Results Amid Rare Disease Development Hurdles

Event summary

  • Ultragenyx Pharmaceutical will host a conference call on February 12, 2026, at 5:00 p.m. ET.
  • The call will cover the company’s financial results and corporate update for the year ending December 31, 2025.
  • A replay of the call will be available for three months following the live event.
  • Ultragenyx focuses on developing therapies for serious and ultra-rare genetic diseases.

The big picture

Ultragenyx operates in a sector characterized by high development costs, regulatory hurdles, and limited patient populations. While rare disease therapies can command premium pricing, the company’s long-term success depends on a consistent flow of new product approvals and effective commercialization strategies. The upcoming call will offer a crucial snapshot of Ultragenyx’s progress in navigating these challenges.

What we're watching

Clinical Progress
The success of Ultragenyx’s pipeline hinges on the advancement of its product candidates, and the call will likely reveal the status of key clinical trials, which could significantly impact investor sentiment.
Commercialization
Given the niche nature of rare disease treatments, Ultragenyx’s ability to effectively commercialize its approved therapies will be critical to sustaining growth and profitability.
Funding Needs
Drug development is capital-intensive, and the company's financial update will provide insight into its cash runway and potential need for future funding rounds.

Ultragenyx Seeks FDA Approval for Sanfilippo Gene Therapy After Long-Term Data

Event summary

  • Ultragenyx submitted a BLA resubmission to the FDA for UX111 (rebisufligene etisparvovec) in January 2026, anticipating a six-month review period.
  • Long-term data (up to 8.5 years) demonstrate sustained reductions in CSF-HS and meaningful improvements in cognitive, communication, and motor function in children with Sanfilippo syndrome Type A (MPS IIIA).
  • Clinical improvements were observed across multiple developmental domains, with some patients reaching milestones not seen in untreated peers.
  • The therapy, originally developed by Abeona Therapeutics, has received multiple designations including Fast Track, Rare Pediatric Disease, and PRIME.

The big picture

UX111 represents a significant advancement in gene therapy for rare, devastating diseases like Sanfilippo syndrome, a market with limited treatment options. The long-term data strengthens the case for gene therapy as a viable treatment modality for neurological disorders, but the high cost and complex logistics of gene therapy delivery pose ongoing challenges for broader adoption. This approval, if granted, could pave the way for similar gene therapy approaches targeting other rare genetic conditions.

What we're watching

Regulatory Risk
The FDA's review timeline and ultimate decision on the BLA resubmission will be critical, as a rejection could significantly impact Ultragenyx's valuation and future development plans.
Market Adoption
The therapy's success will depend on the ability to identify and treat patients early, requiring robust diagnostic capabilities and patient access programs given the disease's rarity and severity.
Long-Term Efficacy
Continued monitoring of patients beyond the 8.5-year mark is necessary to confirm the durability of the observed clinical benefits and identify any potential long-term adverse effects.

Ultragenyx Resubmits MPS IIIA Gene Therapy Application, Aims for Accelerated Approval

Event summary

  • Ultragenyx resubmitted a Biologics License Application (BLA) for UX111, a gene therapy for Sanfilippo syndrome type A (MPS IIIA), to the U.S. FDA on January 30, 2026.
  • The resubmission addresses concerns raised in a Complete Response Letter (CRL) from July 2025 and includes longer-term clinical data.
  • Ultragenyx anticipates a six-month review period, with a potential PDUFA action date in the third quarter of 2026.
  • The therapy, originally developed by Abeona Therapeutics, aims to be the first approved treatment for MPS IIIA, a rare and fatal genetic disorder.

The big picture

The resubmission represents a crucial step for Ultragenyx, as it seeks to bring a first-in-class therapy to market for a devastating rare disease with a limited patient population (estimated 3,000-5,000 in accessible geographies). The FDA’s decision will not only impact Ultragenyx’s prospects but also serve as a precedent for the accelerated approval pathway for gene therapies targeting other rare neurological disorders. Success here could unlock significant value, while rejection would raise questions about the viability of the AAV9 gene therapy approach for MPS IIIA.

What we're watching

Regulatory Risk
Whether the FDA will accept the resubmission and grant accelerated approval hinges on the perceived robustness of the longer-term clinical data and the completeness of the CMC responses, potentially impacting Ultragenyx's valuation.
Clinical Efficacy
The presentation at WORLDSymposium 2026 will be critical in validating the durability of the treatment effect observed in patients, influencing investor confidence and future development timelines.
Market Adoption
The pace at which physicians and families adopt UX111, if approved, will be influenced by the therapy's demonstrated safety profile and the availability of reimbursement, impacting Ultragenyx's revenue projections.

Ultragenyx Revenue Surges, Pipeline Catalysts Loom in 2026

Event summary

  • Ultragenyx exceeded its 2025 revenue guidance, reporting preliminary revenue of $672–$674 million, a 20% increase year-over-year.
  • The company ended 2025 with approximately $735 million in cash and investments.
  • Key 2026 catalysts include potential approvals for DTX401 and UX111, and Phase 3 data for GTX-102 in Angelman syndrome.
  • Crysvita® revenue reached $480–$482 million, while Dojolvi® revenue was $95–$97 million.

The big picture

Ultragenyx's strong 2025 performance and robust pipeline position it as a key player in the rapidly expanding gene therapy market. The company's reliance on regulatory approvals and clinical trial outcomes, however, creates inherent risk. The upcoming data readouts and potential approvals will be pivotal in determining Ultragenyx's long-term valuation and competitive positioning within the rare disease therapeutic space.

What we're watching

Regulatory Risk
The success of Ultragenyx's pipeline hinges on timely FDA approvals for DTX401 and UX111; delays or rejections would significantly impact near-term growth projections.
Clinical Execution
The pivotal Phase 3 data for GTX-102 in Angelman syndrome will be critical; a failure to demonstrate efficacy could dampen investor enthusiasm and impact future development plans.
Commercialization
While Crysvita continues to drive revenue, Ultragenyx’s ability to successfully commercialize its gene therapies and expand Dojolvi’s market penetration will be crucial for sustained growth beyond 2026.

Ultragenyx CEO to Address J.P. Morgan Healthcare Conference

Event summary

  • Ultragenyx CEO Emil Kakkis will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026.
  • The presentation will be webcast live and archived on Ultragenyx's investor relations website.
  • Ultragenyx focuses on developing therapies for rare and ultra-rare genetic diseases.
  • The company aims for time- and cost-efficient drug development.

The big picture

Ultragenyx’s participation in the J.P. Morgan Healthcare Conference signals an effort to engage with key investors and analysts, crucial for maintaining a premium valuation in the increasingly competitive rare disease market. The company’s focus on expedited development processes is a direct response to the high cost and lengthy timelines associated with bringing therapies to market for these niche patient populations. The conference provides a platform to articulate this strategy and address investor concerns about long-term sustainability.

What we're watching

Investor Sentiment
The conference presentation will likely be scrutinized for any shifts in Ultragenyx’s development timelines or commercial strategies, potentially influencing investor perception of the company’s valuation.
Pipeline Progress
The success of Ultragenyx’s strategy hinges on the continued advancement of its pipeline; the presentation should reveal the progress of key product candidates and any emerging challenges.
Competitive Landscape
Increased competition in the rare disease therapeutic space will likely put pressure on Ultragenyx’s pricing and market share, and the conference may offer insights into how the company intends to navigate this environment.

Ultragenyx Submits BLA for GSDIa Gene Therapy, Paving Way for First-in-Class Treatment

Event summary

  • Ultragenyx has completed the rolling submission of a Biologics License Application (BLA) to the U.S. FDA for DTX401 (pariglasgene brecaparvovec), a gene therapy for Glycogen Storage Disease Type Ia (GSDIa).
  • The BLA is supported by data from the Phase 3 GlucoGene study involving 52 patients with up to six years of follow-up.
  • DTX401 demonstrated significant reductions in cornstarch intake and hypoglycemia, alongside improvements in patient-reported quality of life.
  • The company previously received rolling review designation and submitted non-clinical and clinical modules in August 2025, completing the package with the CMC module.

The big picture

Ultragenyx's BLA submission for DTX401 marks a significant advancement in the treatment of GSDIa, a debilitating and life-threatening rare disease. The success of this gene therapy hinges on navigating the stringent regulatory pathway for novel therapies and demonstrating long-term efficacy and safety. This submission underscores the growing focus on gene therapy as a potential treatment modality for rare genetic disorders, a market attracting increasing investment and attention from both pharmaceutical companies and investors.

What we're watching

Regulatory Review
The FDA’s review timeline and potential requests for additional data will be critical in determining the therapy’s market entry, given the complexity of gene therapies and the precedent-setting nature of this application.
Commercialization
The company’s ability to establish a robust manufacturing process and pricing strategy for DTX401 will be key to maximizing returns, considering the high cost of gene therapies and the relatively small patient population (estimated 6,000).
Competitive Landscape
While DTX401 represents a first-in-class treatment, ongoing research into alternative therapies for GSDIa could pose a long-term competitive threat, necessitating continued innovation and differentiation.

Ultragenyx Setrusumab Phase 3 Fails, Triggers Expense Cuts

Event summary

  • Ultragenyx's Phase 3 Orbit and Cosmic trials for setrusumab (UX143) in Osteogenesis Imperfecta (OI) failed to meet primary endpoints (fracture rate reduction).
  • Both trials did achieve statistical significance in secondary endpoints related to bone mineral density (BMD) improvements.
  • Ultragenyx will implement significant expense reductions in response to the disappointing trial results.
  • The Orbit study involved 159 patients across 11 countries, while the Cosmic study enrolled 69 patients across 7 countries.

The big picture

The failure of setrusumab represents a significant setback for Ultragenyx, highlighting the inherent risks in rare disease drug development. While the BMD improvements are encouraging, the lack of fracture rate reduction casts doubt on the drug's clinical utility and commercial viability. This event underscores the challenges of developing treatments for OI, a disease with limited approved therapies and a complex pathophysiology, and will likely lead to increased scrutiny of Ultragenyx's broader development portfolio.

What we're watching

Data Re-analysis
Ultragenyx's ongoing data analysis may reveal previously unseen signals or subgroups where setrusumab demonstrates efficacy, potentially influencing future development strategies.
Financial Impact
The scale of the planned expense reductions will be critical to monitor, as it will directly impact Ultragenyx's near-term profitability and R&D pipeline.
Pipeline Focus
The company's stated focus on other pipeline assets, including gene therapy launches and the Angelman syndrome trial, will be tested as Ultragenyx seeks to offset the UX143 setback.
CID: 513